학술논문

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
Document Type
article
Author
O’Mahony, Denise GRamus, Susan JSouthey, Melissa CMeagher, Nicola SHadjisavvas, AndreasJohn, Esther MHamann, UteImyanitov, Evgeny NAndrulis, Irene LSharma, PriyankaDaly, Mary BHake, Christopher RWeitzel, Jeffrey NJakubowska, AnnaGodwin, Andrew KArason, AdalgeirBane, AnitaSimard, JacquesSoucy, PennyCaligo, Maria AMai, Phuong LClaes, Kathleen BMTeixeira, Manuel RChung, Wendy KLazaro, ConxiHulick, Peter JToland, Amanda EPedersen, Inge SokildeNeuhausen, Susan LVega, Anade la Hoya, MiguelNevanlinna, HeliDhawan, MallikaZampiga, ValentinaDanesi, RitaVaresco, LilianaGismondi, VivianaVellone, Valerio GaetanoJames, Paul AJanavicius, RamunasNikitina-Zake, LieneNielsen, Finn Ciliusvan Overeem Hansen, ThomasPejovic, TanjaBorg, AkeRantala, JohannaOffit, KennethMontagna, MarcoNathanson, Katherine LDomchek, Susan MOsorio, AnaGarcía, María JKarlan, Beth YDe Fazio, AnnaBowtell, DavidMcGuffog, LesleyLeslie, GoskaParsons, Michael TDörk, ThiloSpeith, Lisa-Mariedos Santos, Elizabeth Santanada Costa, Alexandre André BARadice, PaoloPeterlongo, PaoloPapi, LauraEngel, ChristophHahnen, EricSchmutzler, Rita KWappenschmidt, BarbaraEaston, Douglas FTischkowitz, MarcSinger, Christian FTan, Yen YenWhittemore, Alice SSieh, WeivaBrenton, James DYannoukakos, DrakoulisFostira, FlorentiaKonstantopoulou, IreneSoukupova, JanaVocka, MichalChenevix-Trench, GeorgiaPharoah, Paul DPAntoniou, Antonis CGoldgar, David ESpurdle, Amanda BMichailidou, Kyriaki
Source
British Journal of Cancer. 128(12)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Rare Diseases
Cancer
Breast Cancer
Genetics
Ovarian Cancer
Aetiology
2.1 Biological and endogenous factors
Good Health and Well Being
Humans
Female
Virulence
BRCA1 Protein
BRCA2 Protein
Ovarian Neoplasms
Genetic Predisposition to Disease
Breast Neoplasms
HEBON Investigators
GEMO Study Collaborators
AOCS Group
CZECANCA Consortium
Consortium of Investigators of Modifiers of BRCA1/2
Evidence-based Network for the Interpretation of Germline Mutant Alleles Consortium
Public Health and Health Services
Oncology & Carcinogenesis
Oncology and carcinogenesis
Language
Abstract
BackgroundThe distribution of ovarian tumour characteristics differs between germline BRCA1 and BRCA2 pathogenic variant carriers and non-carriers. In this study, we assessed the utility of ovarian tumour characteristics as predictors of BRCA1 and BRCA2 variant pathogenicity, for application using the American College of Medical Genetics and the Association for Molecular Pathology (ACMG/AMP) variant classification system.MethodsData for 10,373 ovarian cancer cases, including carriers and non-carriers of BRCA1 or BRCA2 pathogenic variants, were collected from unpublished international cohorts and consortia and published studies. Likelihood ratios (LR) were calculated for the association of ovarian cancer histology and other characteristics, with BRCA1 and BRCA2 variant pathogenicity. Estimates were aligned to ACMG/AMP code strengths (supporting, moderate, strong).ResultsNo histological subtype provided informative ACMG/AMP evidence in favour of BRCA1 and BRCA2 variant pathogenicity. Evidence against variant pathogenicity was estimated for the mucinous and clear cell histologies (supporting) and borderline cases (moderate). Refined associations are provided according to tumour grade, invasion and age at diagnosis.ConclusionsWe provide detailed estimates for predicting BRCA1 and BRCA2 variant pathogenicity based on ovarian tumour characteristics. This evidence can be combined with other variant information under the ACMG/AMP classification system, to improve classification and carrier clinical management.